ZIOPHARM Oncology Inc (ZIOP) Shares Sold by Piermont Capital Management Inc.
Piermont Capital Management Inc. lowered its position in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 15.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 85,500 shares of the biotechnology company’s stock after selling 15,270 shares during the quarter. Piermont Capital Management Inc. owned about 0.06% of ZIOPHARM Oncology worth $532,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board bought a new position in shares of ZIOPHARM Oncology in the second quarter worth $1,010,000. Vident Investment Advisory LLC increased its holdings in shares of ZIOPHARM Oncology by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 137,976 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 22,996 shares during the period. Old West Investment Management LLC bought a new position in shares of ZIOPHARM Oncology in the first quarter worth $205,000. Morgan Stanley increased its holdings in shares of ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after purchasing an additional 324,774 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in shares of ZIOPHARM Oncology in the second quarter worth $622,000. 41.94% of the stock is currently owned by hedge funds and other institutional investors.
ZIOPHARM Oncology Inc (ZIOP) opened at 6.33 on Thursday. ZIOPHARM Oncology Inc has a 1-year low of $4.84 and a 1-year high of $7.88. The company has a 50-day moving average price of $5.85 and a 200-day moving average price of $6.25. The company’s market cap is $890.20 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the firm earned ($1.01) earnings per share. The business’s quarterly revenue was down 5.9% on a year-over-year basis. On average, analysts expect that ZIOPHARM Oncology Inc will post ($0.56) EPS for the current fiscal year.
A number of research analysts recently commented on the company. BidaskClub cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine cut ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Finally, HC Wainwright assumed coverage on ZIOPHARM Oncology in a research note on Thursday, June 1st. They issued a “buy” rating and a $9.50 target price on the stock. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $13.17.
WARNING: “ZIOPHARM Oncology Inc (ZIOP) Shares Sold by Piermont Capital Management Inc.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/28/ziopharm-oncology-inc-ziop-shares-sold-by-piermont-capital-management-inc.html.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.